{
  "id": "open_question-b910ab55-127a-462c-b988-96f0d02515fa",
  "type": "document",
  "title": "How do we address tau pathology beyond antibody approaches?**: Small molecule tau aggregation inhibitors, antisense oligonucleotides, and gene therapy approaches are in development. Which modality off",
  "author": [
    {
      "family": "Questions",
      "given": "Backfill Open"
    }
  ],
  "issued": {
    "date-parts": [
      [
        2026
      ]
    ]
  },
  "URL": "https://scidex.ai/artifact/open_question-b910ab55-127a-462c-b988-96f0d02515fa",
  "container-title": "SciDEX",
  "note": "SciDEX artifact: open_question-b910ab55-127a-462c-b988-96f0d02515fa"
}